抗HIV治療ガイドライン(2022年3月発行)

XVI医療従事者におけるHIVの曝露対策

文献

  1. Bell DM: Occupational risk of human inmmunodeficiency virus infection in healthcare workers: an overview. Am J Med. 102 (Suppl. 5B): 9-15, 1997.
  2. Ippolito G, Puro V, De Carli G. The risk of occupational human innunodeficiency virus infection in health care workers. Arch Intern Med. 153: 1451-8, 1993.
  3. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med. 341(6):385-93.1999.
  4. Recommendations for Use of Antiretroviral Drugs during Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States (Last updated Dec. 30,2021). https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new-guidelines
  5. Cohen MS, Chen YQ, McCauley M, et al. HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 365:493-505. 2011.
  6. Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 34(9):875-92. 2013.
  7. Expert Advisory Group on AIDS. Providing expert scientific advice on HIV. Updated recommendation for HIV post-exposure prophylaxis (PEP) following occupational exposure to a source with undetectable HIV viral load.
    https://www.gov.uk/government/publications/eaga-guidance-on-hiv-post-exposure-prophylaxis
  8. Post-exposure Prophylaxis for HIV: Australian National Guidelines. https://www.ashm.org.au/resources/post-exposure-prophylaxis-for-hiv-australian-national-guidelines/
  9. Young TN, Arens FJ, Kennedy GE, et al. Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure. Cochrane Database Syst Rev. (1):CD002835. 2007.
  10. 厚生労働省通知:健疾発0909 第1号「労災保険におけるHIV感染症の取扱いについて」平成22年9月9日.
  11. New York State Department of Health AIDS Institute. Clinical guideline program. PEP to Prevent HIV infection. (Nov 2021) https://www.hivguidelines.org/pep-for-hiv-prevention/pep/#tab_2
  12. HIV post-exposure prophylaxis. Guidance from the UK Chief Medical Officers’ Expert Advisory Group on AIDS. Department of Health, 2008.
    https://www.gov.uk/government/publications/eaga-guidance-on-hiv-post-exposure-prophylaxis
  13. Eye of the Needle. United Kingdom Surveillance of Significant Occupational Exposures to Bloodborne Viruses in Healthcare Workers. Public Health England. December 2014.
  14. Lockman S, Brummel SS, Ziemba L, et al. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet 397:1276-1292, 2021.
  15. The European Guidelines for Treatment of HIV Infected Adults in Europe (European AIDS Clinical Society, version 11.0 - October 2021). https://eacs.sanfordguide.com
  16. Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med.379(10):979-81. 2018
  17. Zash R, Holmes L, Diseko M, et al. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. N Engl J Med. 2019 Aug 29;381:827-840.
  18. Zash R, Holmes L, Diseko M, et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana. 23rd International AIDS Conference 2020. #OAXLB0102.
  19. de Boer MG, van den Berk GE, van Holten N, et al. Intolerance of dolutegravir containing cART regimens in real life clinical practice. AIDS. 30(18):2831-4, 2016.
  20. 関根祐介、平野智理、冨樫英晶、他. 東京医科大学におけるドルテグラビルの使用状況と有害事象について.
    2015年 第29回日本エイズ学会学術集会(東京)、抄録番号O7-035.
  21. HRD共同調査協議会. HIV感染症治療薬共同使用成績調査2018年報告書(1997年8月~2018年3月31日)
    http://www.nihs.go.jp/mhlw/jouhou/hrd/hrd-2018.pdf.
  22. Cardo DM, Culver DH, Ciesielski CA, et al.: A case-control study of HIV seroconversion in healthcare workers after percutaneous exposure. N. Engl. J. Med. 337: 1485-90, 1997.
  23. Notes from the Field: Occupationally Acquired HIV Infection Among Health Care Workers-United States, 1985-2013. MMWR January 9, 2015.

PAGE TOP